- Home
- SPRO vs ENTA Comparison
SPRO vs ENTA Comparison
Compare SPRO & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- ENTA
- Stock Information
- Founded
- SPRO 2013
- ENTA 1995
- Country
- SPRO United States
- ENTA United States
- Employees
- SPRO N/A
- ENTA N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- SPRO Health Care
- ENTA Health Care
- Exchange
- SPRO Nasdaq
- ENTA Nasdaq
- Market Cap
- SPRO 164.4M
- ENTA 160.3M
- IPO Year
- SPRO 2017
- ENTA 2013
- Fundamental
- Price
- SPRO $2.91
- ENTA $7.89
- Analyst Decision
- SPRO Buy
- ENTA Buy
- Analyst Count
- SPRO 4
- ENTA 4
- Target Price
- SPRO $5.00
- ENTA $18.00
- AVG Volume (30 Days)
- SPRO 1.6M
- ENTA 181.3K
- Earning Date
- SPRO 08-04-2025
- ENTA 08-04-2025
- Dividend Yield
- SPRO N/A
- ENTA N/A
- EPS Growth
- SPRO N/A
- ENTA N/A
- EPS
- SPRO N/A
- ENTA N/A
- Revenue
- SPRO $44,584,000.00
- ENTA $64,462,999.00
- Revenue This Year
- SPRO N/A
- ENTA N/A
- Revenue Next Year
- SPRO N/A
- ENTA $0.48
- P/E Ratio
- SPRO N/A
- ENTA N/A
- Revenue Growth
- SPRO N/A
- ENTA N/A
- 52 Week Low
- SPRO $0.51
- ENTA $4.09
- 52 Week High
- SPRO $3.09
- ENTA $17.24
- Technical
- Relative Strength Index (RSI)
- SPRO 71.62
- ENTA 67.33
- Support Level
- SPRO $2.79
- ENTA $6.95
- Resistance Level
- SPRO $3.03
- ENTA $8.23
- Average True Range (ATR)
- SPRO 0.12
- ENTA 0.40
- MACD
- SPRO -0.08
- ENTA 0.00
- Stochastic Oscillator
- SPRO 43.75
- ENTA 75.11
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.